{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:20:30Z","timestamp":1772119230259,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00210-025-03797-6","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T05:19:55Z","timestamp":1738041595000},"page":"8813-8823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the efficacy of nano-cyclosporine A in mice model of ulcerative colitis: a meta-analysis"],"prefix":"10.1007","volume":"398","author":[{"given":"Aqsa","family":"Mehreen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiza","family":"Batool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uzma Azeem","family":"Awan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Shabnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Haider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaista","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madiha","family":"Ghazanfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fakhar","family":"Ud-Din","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Irfan","family":"Siddique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rida Fatima","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"3797_CR1","unstructured":"Automeris.oi, Extract data from charts (2024)"},{"issue":"1\u20132","key":"3797_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijpharm.2014.07.009","volume":"473","author":"A Beloqui","year":"2014","unstructured":"Beloqui A et al (2014) pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int J Pharm 473(1\u20132):203\u2013212","journal-title":"Int J Pharm"},{"key":"3797_CR3","doi-asserted-by":"publisher","unstructured":"Berre CL, HS, Peyrin-Biroulet L (2023) Ulcerative colitis. Lancet 402. https:\/\/doi.org\/10.1016\/S0140-6736(23)00966-2","DOI":"10.1016\/S0140-6736(23)00966-2"},{"key":"3797_CR4","doi-asserted-by":"publisher","unstructured":"Courthion H, MT, Rousseaux C, M\u00f6ller M, Gurny R, Gabriel D, Self-assembling polymeric nanocarriers to target inflammatory lesions in ulcerative colitis. J Control Release, 2017. https:\/\/doi.org\/10.1016\/j.jconrel.2017.07.044","DOI":"10.1016\/j.jconrel.2017.07.044"},{"key":"3797_CR5","doi-asserted-by":"publisher","unstructured":"Cui M, FZ, Song M, Zhou T, Wang Y, Liu K (2022) Phragmites rhizoma polysaccharide-based nanocarriers for synergistic treatment of ulcerative colitis. Int J Biol Macromol 220. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.07.245. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.07.245","DOI":"10.1016\/j.ijbiomac.2022.07.245"},{"key":"3797_CR6","doi-asserted-by":"publisher","unstructured":"Guada M, BA, Alhouayek M, Muccioli G.G, Dios-Vi\u00e9itez M.D.C, Pr\u00e9at V, Blanco-Prieto MJ (2016) Cyclosporine A-loaded lipid nanoparticles in inflammatory bowel disease treatment. Int J Pharm. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.03.012","DOI":"10.1016\/j.ijpharm.2016.03.012"},{"key":"3797_CR7","doi-asserted-by":"publisher","unstructured":"Gut IiESIJ, Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case\u2013control study within a European prospective cohort study. 2009. 58(12): 1606\u20131611. https:\/\/doi.org\/10.1136\/gut.2008.169078","DOI":"10.1136\/gut.2008.169078"},{"key":"3797_CR8","doi-asserted-by":"publisher","unstructured":"Hooijmans, CR, Rovers MM, de Vries RB et al (2014) SYRCLE\u2019s risk of bias tool for animal studies. . BMC Med Res Methodol 14. https:\/\/doi.org\/10.1186\/1471-2288-14-43","DOI":"10.1186\/1471-2288-14-43"},{"key":"3797_CR9","doi-asserted-by":"publisher","unstructured":"Jones GR, LM, Plevris N (2019) IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. Gutt. https:\/\/doi.org\/10.1136\/gutjnl-2019-318936","DOI":"10.1136\/gutjnl-2019-318936"},{"key":"3797_CR10","doi-asserted-by":"publisher","unstructured":"Kazemifard N, Golestani N, Jahankhani K, Farmani, M, Ghavami SB (2024) Ulcerative colitis: the healing power of macrophages. Tissue Barriers. https:\/\/doi.org\/10.1080\/21688370.2024.2390218","DOI":"10.1080\/21688370.2024.2390218"},{"key":"3797_CR11","doi-asserted-by":"publisher","unstructured":"Kobayashi T, Siegmund B, Le Berre C et al (2020) Ulcerative colitis. Nat Rev Dis Primers 6. https:\/\/doi.org\/10.1038\/s41572-020-0205-x","DOI":"10.1038\/s41572-020-0205-x"},{"key":"3797_CR12","doi-asserted-by":"publisher","unstructured":"Lee J, SA, Hlaing SP, Kwak D, Kim H, Kim J, Lee E.H,Yoo J-W (2022) Cupriavidus necator-produced polyhydroxybutyrate\/Eudragit FS hybrid nanoparticles mitigates ulcerative colitis via colon-targeted delivery of cyclosporine A. Pharmaceutics 14. https:\/\/doi.org\/10.3390\/pharmaceutics14122811","DOI":"10.3390\/pharmaceutics14122811"},{"key":"3797_CR13","doi-asserted-by":"publisher","unstructured":"Naeem M, LJ, Oshi MA, Cao J, Hlaing SP, Im E, Jung Y, Yoo JW (2020) Colitis-targeted hybrid nanoparticles-in-microparticles system for the treatment of ulcerative colitis. Acta Biomaterialia. https:\/\/doi.org\/10.1016\/j.actbio.2020.09.017","DOI":"10.1016\/j.actbio.2020.09.017"},{"key":"3797_CR14","doi-asserted-by":"publisher","unstructured":"Naeem M, BJ, Oshi MA, Kim MS, Moon HR, Lee BL, Im E, Jung Y, Yoo JW (2018) Colon-targeted delivery of cyclosporine A using dual-functional Eudragit\u00ae FS30D\/PLGA nanoparticles ameliorates murine experimental colitis. Int J Nanomedicine. https:\/\/doi.org\/10.2147\/IJN.S157566","DOI":"10.2147\/IJN.S157566"},{"key":"3797_CR15","doi-asserted-by":"publisher","unstructured":"Oshi MA, JL, Kim J, Hasan N, Im E, Jung Y, Yoo J-W (2021) pH-Responsive alginate-based microparticles for colon-targeted delivery of pure cyclosporine A crystals to treat ulcerative colitis. Pharmaceutics 13:9. https:\/\/doi.org\/10.3390\/pharmaceutics13091412","DOI":"10.3390\/pharmaceutics13091412"},{"key":"3797_CR16","doi-asserted-by":"publisher","unstructured":"Page MJ, MJE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"3797_CR17","doi-asserted-by":"publisher","unstructured":"Porter RJ, Kalla R, Ho GT (2020) Ulcerative colitis: recent advances in the understanding of disease pathogenesis. F1000Res. https:\/\/doi.org\/10.12688\/f1000research.20805.1","DOI":"10.12688\/f1000research.20805.1"},{"key":"3797_CR18","doi-asserted-by":"publisher","unstructured":"Sung J, AZ, Long D, Yang C, Merlin D (2022) Oral delivery of IL-22 mRNA-loaded lipid nanoparticles targeting the injured intestinal mucosa: a novel therapeutic solution to treat ulcerative colitis. Biomaterials 288. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121707","DOI":"10.1016\/j.biomaterials.2022.121707"},{"key":"3797_CR19","doi-asserted-by":"publisher","unstructured":"Wu Y, MS, Wang D, Li G, Huang J, Tan S, Bao L, Li Q, Li G, Si L (2019) Pep T1 medicinal nano system for targeted delivery of cyclosporine A to alleviate acute severe ulcerative colitis. Biomater Sci. https:\/\/doi.org\/10.1039\/C9BM00925F","DOI":"10.1039\/C9BM00925F"},{"key":"3797_CR20","doi-asserted-by":"publisher","unstructured":"Xiong M, LY, He H, Hao S, Fang P, Xu M, Chen Y,Chen Y, Yu S,Hu H (2023) Cyclosporine A-loaded colon-targeted oral nanomicelles self-assembly by galactosylated carboxymethyl chitosan for efficient ulcerative colitis therapy. Eur J Pharm Biopharm 189. https:\/\/doi.org\/10.1016\/j.ejpb.2023.06.010","DOI":"10.1016\/j.ejpb.2023.06.010"},{"key":"3797_CR21","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/ibd\/izy123","volume":"24","author":"M Zhang","year":"2018","unstructured":"Zhang M, Merlin D (2018) Nanoparticle-based oral drug delivery systems targeting the colon for treatment of ulcerative colitis. Inflamm Bowel Dis 24:1401","journal-title":"Inflamm Bowel Dis"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03797-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-03797-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03797-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T04:31:10Z","timestamp":1757133070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-03797-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3797"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-03797-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5455017\/v1","asserted-by":"object"}]},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}